These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9148185)

  • 21. Interferon beta-1a during a first demyelinating event.
    Poser CM
    N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188840
    [No Abstract]   [Full Text] [Related]  

  • 22. Health department to fund interferon beta despite institute's ruling.
    Mayor S
    BMJ; 2001 Nov; 323(7321):1087. PubMed ID: 11701567
    [No Abstract]   [Full Text] [Related]  

  • 23. Funding medicines for people with multiple sclerosis.
    Taylor D
    BMJ; 2001 Dec; 323(7326):1379-80. PubMed ID: 11744549
    [No Abstract]   [Full Text] [Related]  

  • 24. The failings of NICE. Doctors treating patients with multiple sclerosis will lose confidence in NICE.
    Ellis SJ
    BMJ; 2001 Feb; 322(7284):491. PubMed ID: 11222442
    [No Abstract]   [Full Text] [Related]  

  • 25. [Magnetic resonance angiography in multiple sclerosis].
    Pati DV; Vorobeĭchik G
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):53-7. PubMed ID: 10629934
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon beta-1a during a first demyelinating event.
    Esmonde TF
    N Engl J Med; 2001 Jan; 344(3):229; author reply 229-30. PubMed ID: 11188841
    [No Abstract]   [Full Text] [Related]  

  • 27. Multiple sclerosis drug prompts rationing fears.
    Dyer O
    BMJ; 1995 Oct; 311(7011):969. PubMed ID: 7580631
    [No Abstract]   [Full Text] [Related]  

  • 28. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
    Rotondi M; Bergamaschi R; Chiovato L
    Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
    [No Abstract]   [Full Text] [Related]  

  • 29. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
    Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
    Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating clinically isolated syndromes suggestive of MS.
    Poser CM
    Lancet; 2007 Dec; 370(9604):2000; author reply 2000-1. PubMed ID: 18083395
    [No Abstract]   [Full Text] [Related]  

  • 31. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment with beta-interferon should be started already after the first attack of MS].
    Söderström M
    Lakartidningen; 2001 Feb; 98(6):587-90, 593-4. PubMed ID: 11475246
    [No Abstract]   [Full Text] [Related]  

  • 33. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient and family fact sheet. Current treatments for multiple sclerosis.
    Kernich CA
    Neurologist; 2005 Mar; 11(2):137-8. PubMed ID: 15733335
    [No Abstract]   [Full Text] [Related]  

  • 36. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multiple sclerosis].
    Offenhäusser M; Martin R
    Med Monatsschr Pharm; 1997 Jun; 20(6):149-57. PubMed ID: 9289627
    [No Abstract]   [Full Text] [Related]  

  • 38. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.
    Filippi M; Rovaris M; Inglese M; Barkhof F; De Stefano N; Smith S; Comi G
    Lancet; 2004 Oct 23-29; 364(9444):1489-96. PubMed ID: 15500893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in the therapy of multiple sclerosis with interferon beta-1a].
    Nervenarzt; 1997 Oct; 68(10 Suppl):1-8. PubMed ID: 9375645
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.